Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. reports news about its commercial biopharmaceutical business, including product revenue, financial guidance and operating updates tied to Recorlev®, Gvoke® and Keveyis®. The company commercializes Recorlev for endogenous Cushing’s syndrome, Gvoke ready-to-use liquid glucagon for severe hypoglycemia and Keveyis for primary periodic paralysis.
Recurring updates also cover development of XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and programs using Xeris’ XeriSol® and XeriJect® technology platforms. Company news includes intellectual property developments for Recorlev, partnership-related revenue, and equity inducement grants under Nasdaq listing rules.
Xeris Biopharma (Nasdaq: XERS) reported exceptional Q2 2025 financial results, with total revenue surging 49% year-over-year to $71.5 million. The company's flagship product Recorlev® led growth with a 136% YoY increase to $31.4 million, driven by a 122% rise in patient numbers. Gvoke® revenue grew 17% to $23.5 million, while Keveyis® declined 13% to $11.5 million.
The company significantly improved its bottom line, reducing net loss by 87% to $1.9 million ($0.01 per share) and achieving positive Adjusted EBITDA of $12.5 million. Based on strong performance, Xeris raised its full-year 2025 revenue guidance to $280-290 million from $260-275 million previously. The company also outlined ambitious long-term targets, including $750 million in total revenue by 2030 and nearly $1 billion in Recorlev net revenue by 2035.
Xeris Biopharma (Nasdaq: XERS), a growing biopharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial and operational results. A replay will be available until August 21, 2025 through various dial-in numbers. Investors can access the webcast through the company's investor relations website.
Xeris Biopharma Holdings (XERS) will host its first hybrid analyst and investor day on June 3, 2025, at 10:00 a.m. EST in New York City. The event will feature presentations from key opinion leaders including Dr. Antonio C. Bianco, Dr. Francesco S. Celi, and Dr. Eliza B. Geer, alongside company management.
The presentations will focus on market dynamics, unmet medical needs, and outlook for Recorlev® and XP-8121, their Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism treatment. The event will include a live Q&A session, with virtual participants able to submit questions. A replay will be available for those unable to attend live.
Xeris Biopharma (Nasdaq: XERS), a growth-oriented biopharmaceutical company, has scheduled the release of its first quarter 2025 financial results for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss their financial and operational performance.
Interested participants can pre-register for the call through the provided link. A replay of the conference call will be available until May 22, 2025, through various international dial-in numbers. Additionally, stakeholders can access the webcast through the company's investor relations page.
Xeris Biopharma Holdings (Nasdaq: XERS) announced changes to its Board of Directors. Ricki Fairley has resigned effective immediately, while John Schmid will not seek re-election at the 2025 Annual Stockholders Meeting, which will reduce the board size to eight members.
The company has appointed James Brady as a new director to fill the immediate vacancy. Brady brings over thirty years of experience from AstraZeneca, where he held various leadership positions, most recently serving as Chief Financial Officer of MedImmune, AstraZeneca's biologics discovery and development division. He currently serves on the Board of Directors and Audit Committee of Verona Pharma plc (Nasdaq: VRNA).
Xeris Biopharma Holdings (Nasdaq: XERS) has received FDA approval for its supplemental new drug application (sNDA) of Gvoke VialDx™, the first concentrated, ready-to-dilute liquid glucagon for use as a diagnostic aid during radiologic examinations in adult patients.
The company has partnered with American Regent for commercialization in the U.S., with Xeris handling product supply while American Regent manages commercialization efforts. The product will be available in 1-count or 10-count packages of 1 mg per 0.2 mL single-dose vials, with market availability expected in Q3 2025.
This development targets the growing procedural gastroenterology market, with an estimated 20 million gastrointestinal endoscopic procedures performed annually. The product is designed to temporarily inhibit movement of the gastrointestinal tract in adult patients during radiologic examinations.
Xeris Biopharma (XERS) reported strong financial results for Q4 and full-year 2024, with record quarterly revenue of $60M (35% growth) and annual revenue of $203M (24% growth). Key product performance includes:
- Gvoke® Q4 revenue: $23.3M (+25% YoY), with 35% market share
- Recorlev® Q4 revenue: $22.6M (+131% YoY)
- Keveyis® Q4 revenue: $11.1M (-21% YoY)
The company ended Q4 with $71.6M in cash, generating $2M in cash flow and $8.3M in Adjusted EBITDA for the quarter. For 2025, Xeris projects total revenue guidance of $255M-$275M, representing over 30% growth at the mid-point.
Xeris Biopharma Holdings (Nasdaq: XERS) has announced it will release its fourth quarter and full-year 2024 financial results before U.S. markets open on March 6, 2025. The company will also provide 2025 financial guidance during this release.
Management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. The company currently has three commercially available products: Recorlev® for endogenous Cushing's syndrome, Gvoke® for severe hypoglycemia treatment, and Keveyis® for primary periodic paralysis. Their pipeline includes XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, along with early-stage programs utilizing their XeriSol® and XeriJect® technology platforms.